Synthesis and in vitro evaluation of thiododecaborated α, α- cycloalkylamino acids for the treatment of malignant brain tumors by boron neutron capture therapy

Abstract

Boron-neutron capture therapy (BNCT) is an attractive technique for cancer treatment. As such, α, α-cycloalkyl amino acids containing thiododecaborate ([B12H11](2-)-S-) units were designed and synthesized as novel boron delivery agents for BNCT. In the present study, new thiododecaborate α, α-cycloalkyl amino acids were synthesized, and biological evaluation of the boron compounds as boron carrier for BNCT was carried out.

The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells

“…The results showed that our compounds exerted selective target in breast cancer cell lines, while they showed no toxic effect against normal cell models. In addition, cellular cytotoxicity is also possibly mediated through the increase of uptake in the cancer cells (Hattori et al, 2014;Miyahara et al, 1993). Hence, the cellular uptake assay for micro-distribution of drug in cells need to be carried out in next studies.…”

Synthesis and Evaluation of Dodecaboranethiol Containing Kojic Acid (KA-BSH) as a Novel Agent for Boron Neutron Capture Therapy

“…The cytotoxicity of KA-BSH was assayed using the water soluble tetrazolium (WST)-8 assay with a cell-counting kit (Wako Pure Chemicals, Osaka, Japan) following a modified version of the manufacturer-provided protocols [ 20 ]. Relative cell survival was calculated according to Equation (1): …”

“…To develop practical materials utilizing 10 B carriers, we previously designed, synthesized, and evaluated various BSH-containing organic compounds, which constitute a new class of tumor-seeking and water-soluble compounds, such as amino acids, peptides, etc. The in vitro evaluation of cytotoxicity, cell-killing effects, and micro-distribution analysis by immunocytochemical technique suggested that BSH-containing, tumor-seeking compounds might be potential lead compounds for developing novel B compounds for BNCT [18][19][20].…”

New Method for Synthesis of Substituted N-Borylated Dipeptides Based on Acetonitrile Derivative of the closo-Dodecaborate Anion

“…An important requirement for compounds used for 10 B-NCT is a high selectivity of accumulation in tumor tissues and a high content of boron in molecules to create the required therapeutic concentration [3]. closo-Dodecaborate anion [B 12 H 12 ] 2attracts close attention of researchers when creating new agents for 10 B-NCT due to its low toxicity and high boron content [4][5][6].…”

“…Yield, 42%. (5). Derivative 4 (0.100 g, 0.2 mmol) was dissolved in acetonitrile (5 mL); concentrated hydrochloric acid (2 mL) was added dropwise, and the mixture was refluxed for 2 h. After cooling, the reaction mixture was extracted three times with 10 mL portions of dichloromethane.…”